Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01753674 · ClinicalTrials.gov registry record · Phase 1
The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome
A Phase 1 study, sponsored by University of Connecticut.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT01753674 is a Phase 1 study that was terminated before completion, run by University of Connecticut. The registered enrollment target is 13 participants.
The verdict
NCT01753674, a Phase 1 study, was terminated before completion, sponsored by University of Connecticut.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
Our hypothesis is that TA-65, a dietary supplement will help to reduce insulin resistance and plasma glucose in individuals classified with metabolic syndrome.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT TA-65
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01753674
The ClinicalTrials.gov registry entry for NCT01753674 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Connecticut, which has 107 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01753674 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01753674 about?
NCT01753674 is a clinical study titled "The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome". Our hypothesis is that TA-65, a dietary supplement will help to reduce insulin resistance and plasma glucose in individuals classified with metabolic syndrome.
What is the current status of trial NCT01753674?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2013-01. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01753674?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), TA-65 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01753674?
This trial is sponsored by University of Connecticut, which has 107 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.